Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)

BACKGROUND: Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below 10%, mainly due to resistance to therapy. We have previously shown that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yanyun, Zens, Philipp, Su, Min, Gemperli, Camila Anna, Yang, Haitang, Deng, Haibin, Yang, Zhang, Xu, Duo, Hall, Sean R. R., Berezowska, Sabina, Dorn, Patrick, Peng, Ren-Wang, Schmid, Ralph Alexander, Wang, Wenxiang, Marti, Thomas Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056724/
https://www.ncbi.nlm.nih.gov/pubmed/33874986
http://dx.doi.org/10.1186/s13046-021-01938-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056724/
https://www.ncbi.nlm.nih.gov/pubmed/33874986
http://dx.doi.org/10.1186/s13046-021-01938-2

Ejemplares similares